ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ECOR
OM (34) HYPR (38) STXS (22) NRXS (36) ⌘ Pro Terminal β†’

electroCore Inc. (ECOR) β€” RQD Stock Rating Cockpit

$7.16 -4.79% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.08

electroCore Inc. (ECOR) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $67.8M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ECOR Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ECOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, electroCore Inc. (NASDAQ: ECOR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $7.16 (-4.79% 1D, market cap $67.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ECOR ranks #839 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ECOR compare to OM and HYPR in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ECOR carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 86.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -28.0%, cap $75.8M) and HYPR (Hyperfine Inc. (Class A)) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $76.1M). Among the 5-stock peer group, ECOR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ECOR?
β–Ό

Per ECOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560258), electroCore Inc. generated $32.0M in revenue (+27.2% YoY), -$14.0M in net income, and -$8.3M in free cash flow against $18.7M in total assets and $6.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.08 (-1.05%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (29/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510029
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (7)Whales (5)SEC (11)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
$13 Bull$6 Base$5 Bear
πŸ“¬ FREE ECOR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ECOR)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
πŸ” WHY ECOR SCORES 29/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (38% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Cash Engine Quality+7/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 86.8% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
37
Grade E$8.39-10.7% Next Q
Q2 (-2Q)
34
Grade E$7.49+3.6% Next Q
Q3 (-1Q)
32
Grade E$7.76-7.7% Next Q
Current
29
Grade E$7.16-9.8% Hist 90D Ξ±
Trajectory: E (37) β†’ E (29)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ECOR Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ECOR currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.40) and Max Pain ($7.52) forces dealer call-delta covering toward $13.33.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ECORβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œECOR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
39.930 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE33% OF RANGE
L: $4$7.16H: $13
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 14 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bearish Warning on ECOR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 86.8% gross margin and -11.29% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (55)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (18)

8/40 institutional & smart-money positioning score with 3/20 macro alignment.

Bull Case: Why Buyers Like ECOR
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ECOR)

  • βœ“Walkthrough of ECOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ECOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.19%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $8.11H $8.11L $7.16C $7.16VOL 65.8K
RES: $13.60SUP: $7.15SMA50: $9.40SMA200: $7.75
$13.19$11.14$9.09$7.04$4.99RES $13.60SUP $7.15$7.162026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ECOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ECOR Butterfly Map β†’ + Track ECOR β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +27.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ECOR today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ECOR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ECOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ECOR)

Health Care Rank #839 of 1015 βš”οΈ OM vs ECOR Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ECOR vs. OM, HYPR, STXS, NRXS)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, electroCore Inc. (ECOR) ranks #839 by composite RQD confidence (29/100, grade E) and #704 by equity capitalization ($67.8M). Within this direct 5-issuer industry benchmark cohort, ECOR leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with ECOR at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ECOR ACTIVE
electroCore Inc.
E 29/100 β€” 86.8% -35.0% -4.79% $67.8M Benchmark Subject
OM
Outset Medical Inc.
E 34/100 β€” 39.1% -28.0% -0.25% $75.8M /om-vs-ecor β†’
HYPR
Hyperfine Inc. (Class A)
D- 38/100 β€” 49.8% -35.0% +0.99% $76.1M /hypr-vs-ecor β†’
STXS
Stereotaxis Inc.
E 22/100 β€” 52.7% -35.0% +2.03% $86.4M /stxs-vs-ecor β†’
NRXS
Neuraxis Inc.
D- 36/100 β€” 84.2% -35.0% -7.43% $89.5M /nrxs-vs-ecor β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001560258 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), electroCore Inc. (ECOR) reported GAAP revenue of $32.0M (+27.2% vs. FY2024 revenue of $25.2M , and +99.8% cumulative change since FY2023) , GAAP net income of -$14.0M, operating cash flow of -$8.2M, and free cash flow of -$8.3M (-18.8% YoY). On the balance sheet, ECOR closed FY2025 with $18.7M in total assets against $6.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $32.0M -$14.0M -$8.2M -$8.3M $18.7M $6.6M
FY2024 (FY) 2024-12-31 $25.2M -$11.9M -$6.9M -$6.9M $20.5M β€”
FY2023 (FY) 2023-12-31 $16.0M -$18.8M -$14.7M -$14.7M β€” β€”

3. ECOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ECOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, electroCore Inc. (NASDAQ: ECOR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $7.16 (-4.79% 1D, market cap $67.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ECOR ranks #839 in composite RQD confidence.

How does ECOR compare to OM and HYPR in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ECOR carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 86.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -28.0%, cap $75.8M) and HYPR (Hyperfine Inc. (Class A)) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $76.1M). Among the 5-stock peer group, ECOR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ECOR?

Per ECOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560258), electroCore Inc. generated $32.0M in revenue (+27.2% YoY), -$14.0M in net income, and -$8.3M in free cash flow against $18.7M in total assets and $6.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ECOR trading relative to its 50-day, 200-day, and 52-week technical levels?

ECOR last traded at $7.16 (-4.79% on volume of 94,139 shares), positioning the stock -23.83% below its 50-day simple moving average ($9.40) and -7.61% below its 200-day simple moving average ($7.75). Across its 52-week range of $4.41 to $12.70, ECOR sits at the 33.2% percentile with a 14-day RSI of 39.9 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($6.26 to $8.06).

Direct Sub-Reports: ECOR RQD Cockpit ECOR 12M Forecast ECOR Earnings & Move ECOR Dividends & DRIP ECOR Insiders & 13F ECOR Whale Options ECOR Profit Sankey ECOR News & Why
ROARABLE RATING BRIEF β€’ RQD 29/100 (E) βœ“ SEC XBRL & RQD VERIFIED

ECOR β€” electroCore Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

electroCore Inc. (ECOR) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $7.16 (-4.79% 1D, market capitalization $67.8M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 86.8%, operating margin of -41.1%, and free cash flow yield of -11.29%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

ElectroCore Inc. (ECOR) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. The market capitalization is $0.1B. The company reported FY 2025 revenue of $32.0M, up from $25.2M in FY 2024 and $16.0M in FY 2023.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), electroCore Inc. (ECOR) reported $32.0M in annual revenue (up from $25.2M in FY2024, +27.2% YoY) and -$14.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($16.0M revenue, -$18.8M net income) through FY2025, ECOR scaled operating cash flow to -$8.2M and free cash flow to -$8.3M, backed by $18.7M in total assets against $6.6M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -11.29% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $4.41 – $12.70 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -41.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations. A prospective investor should note that the absence of mapped links means the second-order effects of device regulation, reimbursement, or component supply cannot be traced from the provided data. The watch point is the 510(k) and Quell program outcome referenced in the news, since a regulatory or commercial result there would be the most likely first-order event with ripple potential.

  • Key Question #1: Can ECOR sustain or expand its -41.1% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $32.0M and free cash flow of -$8.3M, how will capital allocation balance growth reinvestment against $6.6M in total debt?
  • Key Question #3: How sensitive is ECOR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ECOR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for electroCore Inc. (ECOR) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ECOR Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ECOR Bull vs. Bear Conversation Board β€” What's Your Call at $7.16?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ECOR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ECOR:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $9.48 (+26.1%)
πŸ“Œ Pinned Debate

Revenue grew from $16.0M in FY 2023 to $32.0M in FY 2025 while gross margin stands at 86.8%.

Long ECOR at $7.52 targeting $9.48. Revenue grew from $16.0M in FY 2023 to $32.0M in FY 2025 while gross margin stands at 86.8%.. Institutional whale score is 5/20 and the risk/reward vs. the $4.41 52-week low is skewed heavily in favor of bulls.

EarningsSniper πŸ‚ BULL

Both sides have a point here β€” ECOR's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk RQD DEBATE OPENER β€’ Hedged Event Driven 🐻 BEARISH 🎯 Target: $5.87 (-21.9%)
Spot @ $7.52

Free cash flow was -$8.3M in FY 2025 against $7.0M of cash, with ROIC at -35% and FCF yield at -11.29%.

Here is the bear case nobody on the bull side wants to address on ECOR: Free cash flow was -$8.3M in FY 2025 against $7.0M of cash, with ROIC at -35% and FCF yield at -11.29%.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Electromedical & Electrotherapeutic Apparatus triggers a 12-15% air pocket.

LIVE TAPE